Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

35.55 +1.79 (+5.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
From Scholar Rock
Via Business Wire
Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer
From Scholar Rock
Via Business Wire
Scholar Rock Provides Corporate Update and Highlights Priorities for 2023
From Scholar Rock
Via Business Wire
Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Scholar Rock
Via Business Wire
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy
From Scholar Rock
Via Business Wire
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer
From Scholar Rock
Via Business Wire
Scholar Rock to Participate in Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA
From Scholar Rock
Via Business Wire
Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting
From Scholar Rock
Via Business Wire
Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy
From Scholar Rock
Via Business Wire
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
From Scholar Rock
Via Business Wire
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
From Scholar Rock
Via Business Wire
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
From Scholar Rock
Via Business Wire
Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare Conference
From Scholar Rock
Via Business Wire
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
From Scholar Rock
Via Business Wire
Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
From Scholar Rock
Via Business Wire
Scholar Rock Announces $205 Million Registered Direct Offering
From Scholar Rock
Via Business Wire
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference
From Scholar Rock
Via Business Wire
Scholar Rock to Present at Jefferies Global Healthcare Conference 2022
From Scholar Rock
Via Business Wire
Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities
From Scholar Rock
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.